Massachusetts-based pharmaceutical company Intarcia Therapeutics is moving forward with plans to market a subcutaneous device that would deliver a daily dose of the anti-retroviral medicine. They’ve just secured $206 million in funding to better research the mini-osmotic pump; a tiny implant that is inserted beneath the skin in order to treat chronic illnesses like HIV and Type II diabetes.